Major advances in cancer therapy result from development of multidrug chemotherapy regimens. Besides death from tumor progression, infections are currently one of the major causes of mortality and morbidity. Because of the risk of complications and mortality, the treatment for febrile neutropenia is admission to hospital and administration of broad-spectrum antibiotics. Response rates of initial antimicrobial treatment vary considerably (40-92%). Due to the heterogeneity of populations in randomized studies, comparison of efficacy and identification of risk factors is limited. This is the main reason why
Introduction
The last two decades have seen major advances in cancer therapy. As a result of the development of multidrug chemotherapy reg- imens, testicular and ovarian neoplasms, choriocarcinoma. Wilm's tumor, small-cell lung carcinoma, leukemia in children and adults, and malignant lymphoma have become potentially curable, even if the disease is advanced. Increasing attention is therefore being paid to the side effects of intensive chemotherapy. Besides death from tumor progression, infections are currently one of the major causes of mortality and morbidity. Because of the risk of complications and mortality, the treatment of febrile neutropenia is admission to hospital and administration of broad-spectrum antibiotics, usually a combination of a broad-spectrum ß-lactam and an aminoglycoside [1] .
Extensive research in management of infections in cancer patients has been conducted. Major research activities in Europe were carried out by the EORTC (European Organization for Research and Treatment of Cancer) [2] , which has organized 13 international prospective studies since 1970. In addition, in Italy the GIMEMA (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto) study group conducted 7 studies and in Germany the PEG (Paul-Ehrlich-Gesellschaft) study group 3 studies [3, 4] . The response rates of prospective studies of antimicrobial treatment vary considerably (40-92%), and the heterogeneity of the study populations limits comparisons of efficacy [1] . In addition, all studies were therapeutically oriented and compared two or more therapeutic regimens. In contrast to randomized antibiotic treatment protocols, only a small number of studies focused on the identification of risk factors, in particular of the Invasive Fungal Infection Co-operative Group of the EORTC, which were recently published [5, 6] . However, these evaluations were limited to fungal infections only [5, 6] .
It is generally recognized that the risk of morbidity and mortality is high following allogeneic bone marrow transplantation and in prolonged aplasia resulting from induction treatment for acute leukemia. In contrast to these patients with a high risk feature in febrile episodes with neutropenia, certain studies have shown that alternatives such as outpatient treatment [7] [8] [9] [10] [11] , or monotherapy may be safe as well as effective in febrile neutropenia [12] [13] [14] [15] . However, the patient population in which such regimens are safe and effective has yet to be exactly defined [1] . It is generally accepted that response rates are higher in episodes with fever of unknown origin (FUO) than in clinically or microbiologically defined infection (CDI) [16] . In the last 20 years, the rates of FUO have increased while those of CDI and microbiologically defined infections (MDI) have fallen [17] . In episodes with MDI, there has been a pronounced shift in the spectrum of infections since the 1970s away from gram-negative to gram-positive pathogens, primarily coagulase-negative staphylococci and streptococci (particularly viridans species), which are currently blamed for most initial infectious episodes [2] .
Fever can be expected to respond rapidly to antibiotic treatment, if neutropenia has lasted less than 1 week and the neutrophil count is 100-1,000/mm 3 [18] . In North America, the question of whether it is time to redefine febrile neutropenia and its treatment has been under debate since the mid 1990s [11] . 'Is it time to redefine the therapy of febrile neutropenia? A look at outpatient therapy' was the theme of a special symposium at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, which took place in Toronto from 28 September to 1 October 1997. Alternative treatment options might be monotherapy or outpatient treatment in selected low-risk febrile neutropenia.
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At the moment, several questions regarding risk factors of febrile episodes in patients with neutropenia are of particular interest. Talcott et al. [19] showed that febrile neutropenia carried a low risk of complication and a low mortality rate (2-5%) in patients with stable underlying disease and no comorbidity. Therefore, there is a current need for prospective studies on infections in cancer patients not limited to antibiotic therapy, but mainly to risk factors of infection, etiology, resistance patterns and outcome. In Europe, however, there is a need for studies to encourage riskadapted treatment, e.g. outpatient-based concepts or monotherapy treatment of febrile neutropenia. This is the main reason why ESBiC (European Society of Biomodulation and Chemotherapy) is conducting a surveillance study that concentrates more on evaluation of risk factors than on therapeutic outcome of prospective randomized antimicrobial regimens: European Surveillance of Infections in Cancer Patients (ESIC). The present contribution is to determine which patients, if any, are at low risk, and in addition can benefit from firstline treatment with treatment options as monotherapy as well as outpatient treatment.
Aims of the Study
ESIC is prospectively conducted in patients with treatment of cancer, which is the only entry criterion for patient selection. Furthermore, as many study sites as possible in multiple countries in Europe should be involved. Therefore, ESIC study is a prospective, multicenter European (international) risk factor/outcome identification study. The aim of the study is to identify the type and incidence of risk factors for acquisition of infections and for worst outcome.
Study Design
The following data will be documented for stratification:
(a) Malignant disease under antineoplastic therapy, e.g. solid tumor, leukemia, lymphoma or other hematological malignancy.
(b) Treatment regimen (chemotherapy, surgery, multimodal therapy, bone marrow or peripheral stem cell transplantation or others).
(c) Stage of disease (first diagnosis vs. relapse).
If the patient receives antibiotics as prophylaxis/treatment or has acquired an infection, the following data should be documented to identify risk factors:
(1) Exposure to antimicrobial agents (antibiotic treatment/prophylaxis vs. untreated/ not receiving antibiotic/antifungal prophylaxis).
(2) Type of antineoplastic therapy. (10) Antibiotic-relate adverse drug reaction (ADR).
(11) Clinical outcome according to the response criteria (documented on a case record form): -in the treatment of infections, -in the therapy of cancer (for every patient regardless of antibiotics or infection). Apart from univariate, the multivariate analysis with the logistic regression model will be done in each subgroup concerning possible risk factors for outcome. Additionally, the same analysis will be done for worst outcome (death).
The subgroups may be combined or restricted within groups depending on the hypothesis tested if the sample size permits: e.g. limit the survey to those receiving antineoplastic chemotherapy, or exclude individuals with solid tumors.
Conclusion
Only a large amount of prospectively collected and centrally validated data with widescale geographic distribution can help us to find answers how to effectively identify and eliminate those risk factors not only associated with infection, but mainly with worst outcome (infection-related mortality). Search for those risk factors, including etiology and resistance to antimicrobials, based on a large amount of data, may help better to organize therapeutic and prophylactic strategies with particular antimicrobial agents.
